Thomas R. Cannell
2015 - Orexigen Therapeutics
In 2015, Thomas R. Cannell earned a total compensation of $3.3M as Executive Vice President, Chief Operating Officer and President of Global Commercial Products at Orexigen Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $111,627 |
|---|---|
| Option Awards | $2,459,517 |
| Salary | $314,442 |
| Other | $438,157 |
| Total | $3,323,743 |
Cannell received $2.5M in option awards, accounting for 74% of the total pay in 2015.
Cannell also received $111.6K in non-equity incentive plan, $314.4K in salary and $438.2K in other compensation.
Rankings
In 2015, Thomas R. Cannell's compensation ranked 2,768th out of 13,638 executives tracked by ExecPay. In other words, Cannell earned more than 79.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,768 out of 13,638 | 80th |
Division Manufacturing | 983 out of 5,190 | 81st |
Major group Chemicals And Allied Products | 361 out of 1,854 | 81st |
Industry group Drugs | 282 out of 1,528 | 82nd |
Industry Pharmaceutical Preparations | 223 out of 1,182 | 81st |
Source: SEC filing on May 30, 2017.
Cannell's colleagues
We found five more compensation records of executives who worked with Thomas R. Cannell at Orexigen Therapeutics in 2015.
2015
Michael Narachi
Orexigen Therapeutics
Chief Executive Officer
2015
Joseph Hagan
Orexigen Therapeutics
Former Chief Business and Financial Officer
2015
Preston Klassen
Orexigen Therapeutics
Executive Vice President, Global Product Development
2015
Heather Turner
Orexigen Therapeutics
General Counsel
2015
Thomas Lynch
Orexigen Therapeutics
General Counsel
News
Eleven Biotherapeutics CEO Steven Kelly receives $3.5M in 2023
April 29, 2024
Eleven Biotherapeutics CEO Thomas Cannell's 2022 pay falls 72% to $1.4M
April 28, 2023
Eleven Biotherapeutics CEO Thomas Cannell's 2021 pay jumps 189% to $4.9M
April 28, 2022
Eleven Biotherapeutics CEO Thomas Cannell's 2020 pay jumps 21% to $1.7M
March 25, 2021
Eleven Biotherapeutics CEO Thomas Cannell's 2019 pay falls 30% to $1.4M
March 30, 2020
Eleven Biotherapeutics CEO Thomas Cannell receives $2M in 2018
April 30, 2019